0
0
DENVER, CO – Researchers at the University of Colorado Anschutz Medical Campus have unveiled a revolutionary method for treating urinary tract infections (UTIs), demonstrating significantly higher effectiveness compared to traditional antibiotic therapies. This innovative approach utilizes nanogels combined with a specialized peptide to deliver the antibiotic gentamicin directly into infected bladder cells, resulting in the elimination of over 90% of bacteria in lab tests.
The study, published in Nanomedicine, highlights the potential of this technology to transform UTI treatment and potentially provide a cure for recurrent infections. The researchers found that nanogels can carry 36% more gentamicin into infected cells compared to conventional methods, while also minimizing harm to healthy cells.
“We prove not only that this technology is doable but could be very effective for future clinical use and can potentially lead towards an eventual cure of recurrent infections,” stated Michael Schurr, PhD, associate professor in the Department of Immunology & Microbiology at the University of Colorado School of Medicine, and senior author of the paper.
A key advantage of this method is its precise drug delivery. The nanogels release the antibiotic rapidly, allowing for quicker and more efficient elimination of bacteria within the bladder. This targeted approach minimizes side effects and reduces the risk of antibiotic resistance, a growing concern with traditional treatments.
“We believe this new approach offers a more effective treatment by delivering the drug directly to the infected cells, allowing it to precisely target and eliminate the infection,” explained Devatha Nair, PhD, associate professor in craniofacial biology at the University of Colorado School of Dental Medicine, and co-author of the paper.
The potential of this nanogel-based drug delivery system extends beyond UTIs. Researchers believe it could be adapted for treating other infections, including periodontal disease. This interdisciplinary project involved collaborations across multiple schools and colleges within the CU Anschutz Medical Campus, showcasing the power of combined expertise in polymer chemistry, pharmacology, microbiology, and urogynecology.
Humberto Escobedo, PhD, the lead author, played a pivotal role in developing the targeted drug delivery system. Marsha K. Guess, MD, MS, and her team, in collaboration with Schurr’s lab, ensured the approach was designed for optimal translation to human clinical trials.
“This is an exciting advancement for the delivery of medicine and the potential to improve the quality of life for many people,” said Schurr. “Advancing research to develop more effective, long-lasting treatments is a crucial step in enhancing overall health and well-being.”
The researchers are optimistic that this breakthrough will pave the way for more effective and less toxic treatments for various infections, revolutionizing patient care worldwide.
Disclaimer: It is important to note that this research is based on laboratory and animal model studies. While the results are promising, further clinical trials are necessary to confirm the safety and efficacy of this nanogel-based treatment in humans. This news article is for informational purposes only and should not be taken as medical advice. Always consult with a healthcare professional for diagnosis and treatment of any1 medical condition.
